Dendreon Corp fka DNDNQ

[ocyanblue]

Since Vital-1 continued after the interim failed, there wasn't an imbalance of deaths against the treatment to warrant stopping the trial. However, since the interim occurred in early Jan where CEGE estimated 1H08, it likely meant that the interim did occur a few months earlier than CEGE had modeled the drug effect for. That is, patients on the treatment arm were dying faster than projected. If this trend continues, it will not bode well for Vital-1.